Yamo Pharmaceuticals a clinical-stage pharmaceutical company which has developed L1-79, an oral treatment that appears to impact the core symptoms of autism, including socialization and communication developing L1-79, a novel therapy that targets the core symptoms of autism and has been well-tolerated by clinical trial patients to-date. The mechanism of action for L1-79 addresses both the central nervous system and metabolic s...
Yamo Pharmaceuticals a clinical-stage pharmaceutical company which has developed L1-79, an oral treatment that appears to impact the core symptoms of autism, including socialization and communication developing L1-79, a novel therapy that targets the core symptoms of autism and has been well-tolerated by clinical trial patients to-date. The mechanism of action for L1-79 addresses both the central nervous system and metabolic symptoms of autism.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.